title: alpha-(3,4-dimethyoxyphenyl)-3,4-dihydro-6,7-dimethoxy-alpha- [(4-methylphenyl)thio]-2(1H)-isoquinolineheptanenitrile (CL 329,753): a novel chemosensitizing agent for P-glycoprotein-mediated resistance with improved biological properties compared with verapamil and cyclosporine A.
abstract: Agents that inhibit P-glycoprotein may restore sensitivity to some antitumor drugs in cancer patients. Optimization of the specificity and potency of one class of chemosensitizing agents related to verapamil has led to the identification of alpha-(3,4-dimethyoxyphenyl)-3,4-dihydro-6, 7-dimethoxy-alpha-[(4-methylphenyl) thio]-2(1H)-isoquinolineheptanenitrile, designated CL 329,753. In vitro, 0.1 to 2.0 microM CL 329,753 restored sensitivity to drugs in the multidrug resistance (MDR) phenotype in cell lines that overexpress P-glycoprotein. CL 329,753 was greater than 10-fold more potent and efficacious than cyclosporine A or verapamil in vitro, particularly in cells that express high levels of P-glycoprotein. The enhanced activity of CL 329,753 may be related to its inability to be transported by P-glycoprotein, since low drug accumulation of cyclosporine or verapamil but not CL 329,753 was found in P-glycoprotein-containing cells, yet all three agents inhibited vinblastine binding to membranes containing P-glycoprotein and inhibited photoaffinity labeling of P-glycoprotein. In vivo, CL 329,753 resensitized drug-resistant tumors to vinblastine or doxorubicin in an ascitic or solid tumor model, respectively. No alteration in the plasma pharmacokinetic profile of doxorubicin by CL 329,753 has been found. Furthermore, the compound had 70-fold less calcium channel antagonistic activity compared with verapamil.
authors.affiliation: Department of Oncology and Immunology, Wyeth-Ayerst Research, Pearl River, NY 10965, USA. Greenblm@war.wyeth.com
authors.forename: L M
authors.initials: LM
authors.lastname: Greenberger
authors.forename: K I
authors.initials: KI
authors.lastname: Collins
authors.forename: T
authors.initials: T
authors.lastname: Annable
authors.forename: J P
authors.initials: JP
authors.lastname: Boni
authors.forename: M K
authors.initials: MK
authors.lastname: May
authors.forename: F M
authors.initials: FM
authors.lastname: Lai
authors.forename: R
authors.initials: R
authors.lastname: Kramer
authors.forename: R V
authors.initials: RV
authors.lastname: Citeralla
authors.forename: W A
authors.initials: WA
authors.lastname: Hallett
authors.forename: D
authors.initials: D
authors.lastname: Powell
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000037:antagonists & inhibitors*; D000345:Affinity Labels / Q000378:metabolism; D002470:Cell Survival / Q000187:drug effects; D016572:Cyclosporine / Q000494:pharmacology*; D003630:Daunorubicin / Q000378:metabolism; D018432:Drug Resistance, Multiple; D006801:Humans; D007546:Isoquinolines / Q000494:pharmacology*; D014162:Transfection; D014407:Tumor Cells, Cultured; D014700:Verapamil / Q000494:pharmacology*
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000345:Affinity Labels; C103548:CL 329753; D007546:Isoquinolines; D016572:Cyclosporine; D014700:Verapamil; D003630:Daunorubicin